Apellis Prelim Revenues $74 M for SYFOVRE® (pegcetacoplan injection) in Q3

 

• Continued strong demand, with more than 100,000 vials (commercial and sample) distributed to date; growth in week-over-week demand returned starting in August
  
• Permanent J-code effective as of October 1, and more than 95% of all Medicare payers now covering SYFOVRE
  
• Up to 45% reduction of nonsubfoveal GA lesion growth observed between Months 24-30 compared to projected sham in the GALE extension study
  
• Estimated rate of retinal vasculitis continues to be rare at 0.01% per injection

https://www.globenewswire.com/news-release/2023/10/05/2755234/0/en/Apellis-Announces-Preliminary-U-S-Net-Revenues-of-Approximately-74-Million-for-SYFOVRE-pegcetacoplan-injection-in-the-Third-Quarter-of-2023.html